



1. LÉKAŘSKÁ FAKULTA  
UNIVERZITY KARLOVY V PRAZE

VŠEOBECNÁ FAKULTNÍ  
NEMOCNICE V PRAZE



# Growth and development of the child

Tomáš Honzík

Department of Paediatrics and Inherited Metabolic Disorders  
First Faculty of Medicine, Charles University and General University  
Hospital in Prague




## Psychomotor development

gross motor, fine motor development  
language, social interaction

## Physical development

growth, body proportions  
GIT, cardiovascular, lymphatic system





# childhood periods

- Embryonic period (6.day-8 week)
- Fetal period (9 week-birth)
- Newborn (0-28.day)
- Infant (29.day-1 year)
  
- Toddler (1-3.year)
  
- Preschool (3-6.year)
  
- School age, Middle childhood
  
- Adolescence



## Health maintenance visits In the first year 10x 1-19years 11x

### vstupní prohlídka po propuštění z porodnice

**14 dní:** preventivní prohlídka a nasazení vitamínu D

**6 týdnů:** preventivní prohlídka a ev. I. očkování proti rotavirům

**9 týdnů:** I. očkování hexavakcína a ev. pneumokoky, II. očkování proti rotavirům

**3 měsíce:** preventivní prohlídka, III. dávka rotavirů (očkovací látka Rotateq)

**4 měsíce:** preventivní prohlídka a pokračování očkování hexavakcína pneumokoky (II. dávka)

**6 měsíců:** preventivní prohlídka

**8 měsíců:** preventivní prohlídka

**10 měsíců:** preventivní prohlídka

**1 rok:** preventivní prohlídka a očkování hexavakcínou III. dávka, ev. pneumokok

**13-15 měsíců:** očkování spalničky, příušnice, zarděnky I. dávka

**18 měsíců:** preventivní prohlídka

**3 roky:** preventivní prohlídka

**5 let:** preventivní prohlídka a očkování záškrt, tetanus, č. kašel, přeočkování spalničky, příušnice, zarděnky

**7 let:** preventivní prohlídka

**9 let:** preventivní prohlídka

**10 let:** přeočkování záškrt, tetanus, č. kašel, dětská obrna

**11 let:** preventivní prohlídka

**13 let:** preventivní prohlídka a event. nepovinné očkování proti HPV/2 dávka za 6 měs./

**15 let:** preventivní prohlídka

**17 let:** preventivní prohlídka

**19 let:** výstupní preventivní prohlídka





Each child and family is unique; therefore, these Recommendations for Preventive Pediatric Health Care are designed for the care of children who are receiving nurturing parenting, have no manifestations of any important health problems, and are growing and developing in a satisfactory fashion. Developmental, psychosocial, and chronic disease issues for children and adolescents may require more frequent counseling and treatment visits separate from preventive care visits. Additional visits also may become necessary if circumstances suggest concerns. These recommendations represent a consensus by the American Academy of Pediatrics (AAP) and Bright Futures. The AAP continues to emphasize the great importance of continuity of care in comprehensive health supervision and the need to avoid fragmentation of care.

Refer to the specific guidance by age as listed in the *Bright Futures Guidelines* (Hagan JF, Shaw JS, Duncan PM, eds. *Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents*. 4th ed. American Academy of Pediatrics; 2017).

The recommendations in this statement do not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate. The Bright Futures/American Academy of Pediatrics Recommendations for Preventive Pediatric Health Care are updated annually.

Copyright © 2023 by the American Academy of Pediatrics, updated April 2023. No part of this statement may be reproduced in any form or by any means without prior written permission from the American Academy of Pediatrics except for one copy for personal use.

| AGE <sup>1</sup><br>Initial/Interval                   | INFANCY               |                      |                    |         |      |      |                 |                      |       | EARLY CHILDHOOD |                      |       |       |     |     | MIDDLE CHILDHOOD |     |     |     |     |      | ADOLESCENCE |      |      |      |      |      |      |      |      |      |      |   |
|--|-----------------------|----------------------|--------------------|---------|------|------|-----------------|----------------------|-------|-----------------|----------------------|-------|-------|-----|-----|------------------|-----|-----|-----|-----|------|-------------|------|------|------|------|------|------|------|------|------|------|---|
|  | Prenatal <sup>2</sup> | Newborn <sup>3</sup> | 3-5 d <sup>4</sup> | By 1 mo | 2 mo | 4 mo | 6 mo            | 9 mo                 | 12 mo | 15 mo           | 18 mo                | 24 mo | 30 mo | 3 y | 4 y | 5 y              | 6 y | 7 y | 8 y | 9 y | 10 y | 11 y        | 12 y | 13 y | 14 y | 15 y | 16 y | 17 y | 18 y | 19 y | 20 y | 21 y |   |
| <b>HISTORY</b>   | ●                     | ●                    | ●                  | ●       | ●    | ●    | ●               | ●                    | ●     | ●               | ●                    | ●     | ●     | ●   | ●   | ●                | ●   | ●   | ●   | ●   | ●    | ●           | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ● |
| <b>MEASUREMENTS</b>                                    |                       |                      |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Length/Height and Weight                               |                       | ●                    | ●                  | ●       | ●    | ●    | ●               | ●                    | ●     | ●               | ●                    | ●     | ●     | ●   | ●   | ●                | ●   | ●   | ●   | ●   | ●    | ●           | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ● |
| Head Circumference                                     |                       | ●                    | ●                  | ●       | ●    | ●    | ●               | ●                    | ●     | ●               | ●                    | ●     | ●     | ●   | ●   | ●                | ●   | ●   | ●   | ●   | ●    | ●           | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ● |
| Weight for Length                                      |                       | ●                    | ●                  | ●       | ●    | ●    | ●               | ●                    | ●     | ●               | ●                    | ●     | ●     | ●   | ●   | ●                | ●   | ●   | ●   | ●   | ●    | ●           | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ● |
| Body Mass Index <sup>6</sup>                           |                       |                      |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Blood Pressure <sup>6</sup>                            |                       | ★                    | ★                  | ★       | ★    | ★    | ★               | ★                    | ★     | ★               | ★                    | ★     | ★     | ★   | ★   | ★                | ★   | ★   | ★   | ★   | ★    | ★           | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    |   |
| <b>SENSORY SCREENING</b>                               |                       |                      |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Vision <sup>7</sup>                                    |                       | ★                    | ★                  | ★       | ★    | ★    | ★               | ★                    | ★     | ★               | ★                    | ★     | ★     | ★   | ★   | ★                | ★   | ★   | ★   | ★   | ★    | ★           | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    |   |
| Hearing  |                       | ● <sup>8</sup>       | ● <sup>9</sup>     | →       | ★    | ★    | ★               | ★                    | ★     | ★               | ★                    | ★     | ★     | ★   | ★   | ★                | ★   | ★   | ★   | ★   | ★    | ★           | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    |   |
| <b>DEVELOPMENTAL/SOCIAL/BEHAVIORAL/MENTAL HEALTH</b>   |                       |                      |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Maternal Depression Screening <sup>11</sup>            |                       |                      |                    | ●       | ●    | ●    | ●               |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Developmental Screening <sup>12</sup>                  |                       |                      |                    |         |      |      | ●               |                      |       |                 | ●                    |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Autism Spectrum Disorder Screening <sup>13</sup>       |                       |                      |                    |         |      |      |                 |                      |       | ●               |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Developmental Surveillance                             |                       |                      |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Behavioral/Social/Emotional Screening <sup>14</sup>    |                       | ●                    | ●                  | ●       | ●    | ●    | ●               | ●                    | ●     | ●               | ●                    | ●     | ●     | ●   | ●   | ●                | ●   | ●   | ●   | ●   | ●    | ●           | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    |   |
| Tobacco, Alcohol, or Drug Use Assessment <sup>15</sup> |                       |                      |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    |   |
| Depression and Suicide Risk Screening <sup>16</sup>    |                       |                      |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    |   |
| <b>PHYSICAL EXAMINATION<sup>17</sup></b>               |                       | ●                    | ●                  | ●       | ●    | ●    | ●               | ●                    | ●     | ●               | ●                    | ●     | ●     | ●   | ●   | ●                | ●   | ●   | ●   | ●   | ●    | ●           | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    |   |
| <b>PROCEDURES<sup>18</sup></b>                         |                       |                      |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Newborn Blood  |                       | ● <sup>19</sup>      | →                  | →       |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Newborn Bilirubin <sup>21</sup>                        |                       | ●                    |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Critical Congenital Heart Defect <sup>22</sup>         |                       | ●                    |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Immunization <sup>23</sup>                             |                       | ●                    | ●                  | ●       | ●    | ●    | ●               | ●                    | ●     | ●               | ●                    | ●     | ●     | ●   | ●   | ●                | ●   | ●   | ●   | ●   | ●    | ●           | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    |   |
| Anemia <sup>24</sup>                                   |                       |                      |                    |         | ★    |      |                 |                      | ●     | ★               | ★                    | ★     | ★     | ★   | ★   | ★                | ★   | ★   | ★   | ★   | ★    | ★           | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    |   |
| Lead <sup>25</sup>                                     |                       |                      |                    |         |      | ★    | ★               | ● or ★ <sup>26</sup> |       | ★               | ● or ★ <sup>26</sup> | ★     | ★     | ★   | ★   | ★                | ★   | ★   | ★   | ★   | ★    | ★           | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    |   |
| Tuberculosis <sup>27</sup>                             |                       |                      | ★                  |         |      |      |                 |                      |       |                 |                      | ★     | ★     | ★   | ★   | ★                | ★   | ★   | ★   | ★   | ★    | ★           | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    |   |
| Dyslipidemia <sup>28</sup>                             |                       |                      |                    |         |      |      |                 |                      |       |                 | ★                    |       |       |     |     |                  | ★   | ★   | ★   | ★   | ★    | ★           | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    |   |
| Sexually Transmitted Infections <sup>29</sup>          |                       |                      |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    |   |
| HIV <sup>30</sup>                                      |                       |                      |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    |   |
| Hepatitis B Virus Infection <sup>31</sup>              |                       | ★                    |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Hepatitis C Virus Infection <sup>32</sup>              |                       |                      |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Sudden Cardiac Arrest/Death <sup>33</sup>              |                       |                      |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             | ★    |      |      |      |      |      |      |      |      |      |   |
| Cervical Dysplasia <sup>34</sup>                       |                       |                      |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| <b>ORAL HEALTH<sup>35</sup></b>                        |                       |                      |                    |         |      |      |                 |                      |       |                 |                      |       |       |     |     |                  |     |     |     |     |      |             |      |      |      |      |      |      |      |      |      |      |   |
| Fluoride Varnish <sup>37</sup>                         |                       |                      |                    |         |      |      | ● <sup>36</sup> | ● <sup>36</sup>      | ★     |                 | ★                    | ★     | ★     | ★   | ★   | ★                | ★   | ★   | ★   | ★   | ★    | ★           | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    |      |   |
| Fluoride Supplementation <sup>38</sup>                 |                       |                      |                    |         |      |      | ★               | ★                    | ★     |                 | ★                    | ★     | ★     | ★   | ★   | ★                | ★   | ★   | ★   | ★   | ★    | ★           | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    | ★    |   |
| <b>ANTICIPATORY GUIDANCE</b>                           | ●                     | ●                    | ●                  | ●       | ●    | ●    | ●               | ●                    | ●     | ●               | ●                    | ●     | ●     | ●   | ●   | ●                | ●   | ●   | ●   | ●   | ●    | ●           | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    |   |

USA – 6x during infancy  
21x between 1-19 years of age



## Lenght

at birth

**50 cm**

1Y

**75 cm**


2Y

**87cm**


height at age 3.5Y **100 cm**

height at age 5 Y **110 cm**

height at age 10Y **140 cm**



**> 2 years**



## Growth


per month I.: 3-4cm, II.: 2 cm, III-IV.:1cm

2nd Y + **11 cm**

3rd Y + **9 cm**

preschool and school period yearly +5 až 7.5 cm

Puberta 8-11 cm (boys), 6.5-9.5 cm (girls)



Girls at 1.5 y and  
Boys at 2 y  
**50 % of its final height**



## Weight

at birth **3500g**

double

till 4-5 months of life

triple

till 1 year (cca **10.5 kg**)

quadruple

till 2 years (**13 kg**)

at age 5 Y **20 kg (19 kg)**

at age 10Y **30 kg (33 kg)**



## Weight gain


Infants- weekly trim.I.: 150-200g, trim.

II.: 150g, trim.III.: 100g.

Toddlers, preschool, school children yearly **+2 kg**

Puberta yearly **+2.5 až 6 kg**





Breastfed Infants Study (2009-2011)  
Thriving - n=960 children  
versus - not breastfed/shortly breastfed

Initially faster thriving (by 2-3m)  
falls below the curve  
after the first six months

Schematic weight chart, comparison of breastfed and non-breastfed babies. Black - Czech references CAV 1991, red - breastfed 2009

# head circumference

neonate

**34 cm**

6 months

**43 cm**

1 year

**47 cm**

3 years

**50 cm (90% of final brain volume)**



HC 1 cm/month first year of life (2 cm/month first 3 months)



# energy requirements

|                   |                    |
|-------------------|--------------------|
| Preterm neonate   | 120-150kcal/kg/day |
| Infant            | 100kcal/kg/day     |
| 10-year old child | 60-70kcal/kg/day   |
| 20-year old adult | 45 kcal/kg/day     |

## energy requirement for growth

|                  |     |
|------------------|-----|
| Preterm neonate  | 50% |
| 5-year old child | 12% |





## Basal energy expenditure - tissues

|        | Infant | Man(30yrs) | Woman(30yrs) |
|--------|--------|------------|--------------|
| Liver  | 14 %   | 21%        | 21%          |
| Brain  | 44%    | 20%        | 21%          |
| Heart  | 4%     | 9%         | 8%           |
| Kidney | 6%     | 8%         | 9%           |
| Muscle | 6%     | 22%        | 16%          |
| Others | 26%    | 20%        | 25%          |

Neonate


Brain

60%

1000 kcal/day/m<sup>2</sup>



TĚLESNÁ DÉLKA  
Chlapci 0 - 24 měsíců



# growth charts

## SD-standart deviation

determine the extent of mean variation

1 SD= 68%

2 SD= 95%


3 SD= 99.7%

5.perc.= - 1.65 SD

10.perc.= - 1.3 SD

25.perc.= - 0.25 SD

## 50.p identical to the arithmetic average



3.-97.p 94% of the population, wider average 25.-75.p - 50% of the population






**Hmotnost k tělesné výšce (50 - 100 cm)**

Weight-for-height (50 - 100 cm)


Chlapci / Boys



**Body Mass Index (BMI) (0 - 18 roků)**

Body Mass Index (BMI) (0 - 18 years)

Chlapci / Boys





**Genetics**



**Metabolic  
disorders**



**GH deficiency**



## **cong. lense subluxation**

marfanoid habitus

17 years

177cm (90.P), 59kg, BMI18,8

mother 163cm, father 170cm

**Scoliosis, pectus excavatus**

16 years

Hormonal birth control

headache, seizures


**Cerebral plexus thrombosis**







BMI, dívky



Tabulka měření

### Souhrnná tabulka antropometrických dat

Příjmení a jméno: ██████████  
Datum narození: 22.6.2012 Pohlaví: dívka

**Naměřené a vypočtené hodnoty**

| Věk    | Výškový věk (VV) | Výška | Perc. [%] | Z skóre [1] | Perc. na VV [%] | Z skóre na VV [1] |
|--------|------------------|-------|-----------|-------------|-----------------|-------------------|
| [roky] | [roky]           | [cm]  | [%]       | [1]         | [%]             | [1]               |
| 2,18   | 1,93             | 86,5  | 23        | -0,74       | 50              | 0,00              |
| 10,40  | 11,69            | 152,5 | 90        | 1,30        | 50              | 0,00              |


  

| Věk    | Hmotnost [kg] | Perc. [%] | Z skóre [1] | Perc. na VV [%] | Z skóre na VV [1] | BMI [kg/m²] | Perc. [%] | Z skóre [1] | Perc. na VV [%] | Z skóre na VV [1] |
|--------|---------------|-----------|-------------|-----------------|-------------------|-------------|-----------|-------------|-----------------|-------------------|
| [roky] | [kg]          | [%]       | [1]         | [%]             | [1]               | [kg/m²]     | [%]       | [1]         | [%]             | [1]               |
| 2,18   | 13,0          | 57        | 0,16        | 72              | 0,58              | 17,4        | 82        | 0,90        | 77              | 0,75              |
| 10,40  | 48,9          | 96        | 1,71        | 83              | 0,95              | 21,0        | 93        | 1,44        | 88              | 1,19              |

Tisknout Zavřít



BMI, cmrapci





Cushing syndrome





weight 9.9 kg (8.1. p.)  
length 83 cm (70. p.)  
HC 48 cm (79. p)

-1.5kg within 5M

Weight for length  
2.P, -1.9SD)


18M old girl



9M girl, at birth 28 cm,  
HC 33cm



6M girl, at birth 34 cm,  
HC 38cm








# Glycogenosis – case report

I/I gravidity, at term,  
BW 3420g, BL 51cm,  
FH: negative

Hospitalisation at the age of 12M:  
acute pyelonephritis L+2cm

ALT **2.45**  $\mu\text{kat/l}$  (N<0.60), AST **2.6**  $\mu\text{kat/l}$  (N<0.69)

at 20M of age admission - mother's request







# Glycogenosis – case report

Doll face  
borderline microcephaly (3.P)  
EEG abnormalities - epilepsy  
normal psychomotor development

## Lab:

ALT **26.61** AST **67.85**

TRG **11.93**

Cholesterol **7.39**, Kys.močová **394**


B-laktát **3.8**,

*Glycemic profile:* asymptomatic night hypoglycemia (**2.2 mmol/l**)






- hepatomegaly
- hepatopathy
- growth failure
- dyslipidemia
- hypoglycemia
- hyperuricemia
- lactic acidosis



Glycogen storage disease typ Ia






hypothyreosis





## Sturge-Weber syndrom






# centiles growth charts changes

2/3 of children change major percentile lines during first 2Y

**LAG-DOWN GROWTH**

**CATCH-UP GROWTH**

Different hormonal regulation



Women 167.2cm, Men 180.1cm/r. 2001

## Growth during puberty

girls 25-30cm

(completed two years after  
menarche, median 15 years /13-  
16.5)

boys 25-30cm (median 16.5  
years /14.5-18.5)

Puberty 15% of final height





# adolescence/puberty

**Adolescence** – refers to the passage from childhood to adulthood,  
*early (10-13 Y), middle (14-16 Y), late (17-20 Y)*

**Puberty** - refers to those biologic changes that  
lead to reproductive capacity

Height during puberty +15-20% (boys 25-30 cm, girls 18-23 cm)  
Muscle mass double between 10-17 years



# beginning of puberty

## Girls:

Menarche is a relatively late pubertal event

8-13 years (average 11 year) first sign of puberty-*Thelarche*

## Boys:


Testicular enlargement

9.5-13.5 years (average 11.5 years)-testes 4-6 ml



# MENARCHE

## Evropa and USA 1840-2000



**CZE**

1895

15.1 let

2001

13.0 let


Now

12.5 let






# Orchidometer







# assessment of pubertal development



(Tanner, Marshall, 1970)




(Tanner, Marshall, 1970)






girls



sequence of pubertal  
events

boys





# growth reference values

Nation wide antropometric studies: first 1895, 6-14 years old children  
*100 000 children*

Every 10 years (1991; 2001) 0-18 years old children  
(cca 3% children of particular age)

Secular trend of growth: 17 years old boys +7,5 cm, girls +4.7 cm


Problem and Caution: breast-fed x bottle-fed infants

applying the charts to adolescence






# growth 1895-2001










**Body Mass Index (BMI)**  
**Porovnání 1991 a 2001**  
1991 and 2001 comparison  
Chlapci / Boys





**Body Mass Index (BMI)**  
**Porovnání 1991 a 2001**  
1991 and 2001 comparison  
Dívky / Girls




1895 versus 2001 adiposity rebound to 50th percentile has shifted down 1.3 years to 4.9 for boys and 1.2 years for girls to 5.2 years



## Study COVID-19 (2021) Overweight and obesity - n=3517 children 11-13 year old boys - 38, 3 and 36.9%



Prevalence of overweight and obesity 2021,  
A boys and B girls




growth failure

Familial short stature


constitutional growth delay



# Case report – constitutional growth delay



# body proportions



Head/trunk ratio

Infants 1/4

Adults 1/8


body surface area:

neonate 0,25 m<sup>2</sup>; 6M 0,45 m<sup>2</sup>; 6L 0,65 m<sup>2</sup>; 10L 1,15 m<sup>2</sup>;











Lymphoid tissue

Acute sinusitis l. dx.



Adenoid hyperplasia





# neonatal reflexes

**Palmar grasp:** (28) 32.wk - 4.months

**Plantar grasp:** till 12 - 14.months

**Moro reflex:** (32) 37 wk – 3.(6). Months

**Rooting reflex, sucking reflex** (32) 36. wk – 6.months

**Walking and placing reflex:** 37. wk

**Asymetric tonic neck reflexes:** (35) 1.months – 5.months

**Babinsky** (till 12.months)

**Parachute reflex** (7-10.months)



## gross motor dev.

Turns head from side to side (1-4 wk)

Head up 45° (1-2M)

Pull to sit, no head lag (3M)

Hands together in midline (3M)

Sits without support, pivots (6M)

Rolls back to stomach (6.5M)







## gross motor dev.

Sits up alone and indefinitely without support (7M)

Crawling (7-8M)

Pulls to standing position (8M)

Walks with support (10M)

Walks alone (12M, range 10-17M)

Walks alone, crawls up stairs (15M)





# drawing

Scribbles (15M)

Imitates vertical stroke (18M)


Imitates horizontal stroke (24M)

Makes vertical and horizontal strokes, not join them to make a cross (30M)

Copies a circle, imitates a cross (36M)

Copies cross and square, draws a man with 2 to 4 parts (+ head) (48M)


Draws triangle from copy (60M)





1. LÉKAŘSKÁ FAKULTA  
UNIVERZITY KARLOVY V PRAZE

VŠEOBECNÁ FAKULTNÍ  
NEMOCNICE V PRAZE







# language

Babbling begins by age 6M

Speaks first real word (12M)

Speaks 4-6 words, jargon, may name a familiar object (ball) (15M)

The number of words 6-10, names pictures (18M)

Speaks two-word sentences (19M)

Puts 3 words together knows 100-270 words (24M)

Refers to self by pronoun („I“), knows full name (30M)

Knows age and sex, counts 3 objects correctly, knows 900 words (36M)



# social and play development

Smiles in response to face, voice (1.5M)

Stares at own hand (4M)

Face to face interaction with a trusted adults (3-6M)

Inhibits to „no“ (7M)

Bangs two cubes (8M)

Separation anxiety (8M)



# social and play development

Uncovers toy (after seeing it hidden) (8M)

Object constancy (9M)

*Object continue to exist even when not seen*

Follows one-step command without gesture-“give it to me“ (10M)

Egocentric pretend play (pretends to drink from cup) (12M)

Indicates some desires or needs by pointing, hugs parents,  
makes tower of 3 cubes (15M)

Uses stick to reach toy (17M)

Pretend play with doll (gives doll bottles) (17M)





# social and play development

During preschool period, play is marked by increasing complexity and imagination, **from simple scripts-shopping, putting baby to bed (2-3 yr)** to more extended scenario involving singular events such as **going to zoo, going on a trip (3-4 yr)** to the creation of scenario that have only been imagined-such as **flying to the moon (4-5 yr)**.

From minimal social interaction with peers during play (**parallel play 1-2 yr**) to **cooperative play (3-4 yr)**